First-trimester placental growth factor as a marker for hypertensive disorders and SGA

被引:37
作者
Cowans, N. J. [1 ]
Stamatopoulou, A. [1 ]
Matwejew, E. [2 ]
von Kaisenberg, C. S. [2 ,3 ]
Spencer, K. [1 ]
机构
[1] King George Hosp, Dept Clin Biochem, Prenatal Res Unit, Goodmayes IG3 8YB, England
[2] Univ Klinikum Schleswig Holstein, Dept Obstet, Kiel, Germany
[3] Hannover Med Sch, Dept Obstet & Gynaecol, D-30625 Hannover, Germany
关键词
pre-eclampsia; SGA; HELLP; screening; adverse outcome; first trimester; UTERINE ARTERY DOPPLER; ELEVATED LIVER-ENZYMES; 2ND-TRIMESTER MATERNAL SERUM; FREE BETA-HCG; ANGIOGENIC FACTORS; 1ST TRIMESTER; EARLY-ONSET; PAPP-A; PREECLAMPSIA; PREGNANCY;
D O I
10.1002/pd.2525
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective The objective of this study was to examine first-trimester maternal serum placental growth factor (PIGF) levels in pregnancies which later develop hypertensive and growth complications. Methods In this case control study, PIGF levels were measured by AutoDELFIA immunoassay platform. There were 47 cases of at least one of the following adverse outcomes: pre-eclampsia (PE), small for gestational age (SGA), haemolysis elevated liver enzymes and low platelets (HELLP) and gestational hypertension (GH) and 452 matched controls. Results PIGF levels were significantly lower in cases of all PE, early PE, HELLP, all SGA, early SGA and SGA without PE, but not in GH, late PE, late SGA. PE with SGA or PE without SGA or HELLP. Conclusion Low levels of first-trimester PIGF provide a good indicator of SGA complications and some hypertensive disorders, in particular severe cases of PE such as early onset and HELLP syndrome. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:565 / 570
页数:6
相关论文
共 41 条
[1]   Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia [J].
Akolekar, R. ;
Zaragoza, E. ;
Poon, L. C. Y. ;
Pepes, S. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 32 (06) :732-739
[2]   FETAL NUTRITION AND CARDIOVASCULAR-DISEASE IN ADULT LIFE [J].
BARKER, DJP ;
GLUCKMAN, PD ;
GODFREY, KM ;
HARDING, JE ;
OWENS, JA ;
ROBINSON, JS .
LANCET, 1993, 341 (8850) :938-941
[3]   Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction [J].
Crispi, F. ;
Llurba, E. ;
Dominguez, C. ;
Martin-Gallan, P. ;
Cabero, L. ;
Gratacos, E. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2008, 31 (03) :303-309
[4]   A review of HELLP syndrome [J].
Curtin W.M. ;
Weinstein L. .
Journal of Perinatology, 1999, 19 (2) :138-143
[5]   THE CLASSIFICATION AND DEFINITION OF THE HYPERTENSIVE DISORDERS OF PREGNANCY [J].
DAVEY, DA ;
MACGILLIVRAY, I .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1988, 158 (04) :892-898
[6]   Primary, secondary, and tertiary prevention of pre-eclampsia [J].
Dekker, G ;
Sibai, B .
LANCET, 2001, 357 (9251) :209-215
[7]   The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age [J].
Erez, Offer ;
Romero, Roberto ;
Espinoza, Jimmy ;
Fu, Wenjiang ;
Todem, David ;
Kusanovic, Juan Pedro ;
Gotsch, Francesca ;
Edwin, Samuel ;
Nien, Jyh Kae ;
Chaiworapongsa, Tinnakorn ;
Mittal, Pooja ;
Mazaki-Tovi, Shali ;
Than, Nandor Gabor ;
Gomez, Ricardo ;
Hassan, Sonia S. .
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2008, 21 (05) :279-287
[8]   Circulating angiogenic factors in gestational proteinuria without hypertension [J].
Holston, Alexander M. ;
Qian, Cong ;
Yu, Kai F. ;
Epstein, Franklin H. ;
Karumanchi, Ananth ;
Levine, Richard J. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 200 (04) :392.e1-392.e10
[9]  
KOGA K, 2009, FERTIL STERIL, DOI DOI 10.1016/J.FERTNSTERT.2009.02.0151
[10]   Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia [J].
Lambert-Messerlian, GM ;
Canick, JA .
PRENATAL DIAGNOSIS, 2004, 24 (11) :876-880